HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nivo-lution in Mesothelioma.

Abstract
The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.See related article by Okada et al., p. 5485.
AuthorsAaron S Mansfield, Marjorie G Zauderer
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 25 Issue 18 Pg. 5438-5440 (Sep 15 2019) ISSN: 1557-3265 [Electronic] United States
PMID31315884 (Publication Type: Journal Article, Comment)
Copyright©2019 American Association for Cancer Research.
Chemical References
  • Nivolumab
Topics
  • Humans
  • Japan
  • Lung Neoplasms
  • Mesothelioma
  • Nivolumab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: